QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
07 févr. 2024 16h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the...
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
16 août 2023 08h00 HE
|
QSAM Biosciences Inc.
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
14 juin 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, June 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the...
QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
23 mai 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, May 23, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for...
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
16 mai 2023 08h30 HE
|
QSAM Biosciences Inc.
Partnership is Latest in Series of RLS Efforts to Expand Industry-Leading CDMO Business and Clinical Trial Capability with Radiopharmaceutical Partners Across U.S. Austin, TX and Lake Zurich, IL,...
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
26 avr. 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 26, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
05 avr. 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
20 mars 2023 08h30 HE
|
QSAM Biosciences Inc.
QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Austin, TX, March 20,...
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
08 mars 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
28 févr. 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...